# Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

> **NCT00970203** · PHASE2 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 13 (actual)

## Conditions studied

- Cancer of Prostate
- Cancer of the Prostate
- Neoplasms, Prostate
- Neoplasms, Prostatic
- Prostate Cancer
- Prostate Neoplasms
- Prostatic Cancer

## Interventions

- **BIOLOGICAL:** androgen ablation (AA)
- **BIOLOGICAL:** DC1 vaccine

## Key facts

- **NCT ID:** NCT00970203
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2018-10-05
- **Final completion:** 2019-10-05
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2020-11-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00970203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00970203, "Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00970203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*